Sangamo BioSciences Inc. | Mutual Funds
Mutual Funds that own Sangamo BioSciences Inc.
SPDR S&P Biotech ETF
4,447,318
4.37%
11,442
1.39%
09/06/2018
Vanguard Total Stock Market Index Fund
2,577,589
2.54%
0
0.01%
07/31/2018
Fidelity Select Biotechnology Portfolio
2,172,462
2.14%
-490,563
0.43%
07/31/2018
iShares Russell 2000 ETF
2,122,547
2.09%
-1,134
0.08%
09/06/2018
Vanguard Extended Market Index Fund
1,338,838
1.32%
42,600
0.03%
07/31/2018
Vanguard Small Cap Index Fund
1,274,430
1.25%
16,395
0.02%
07/31/2018
Wasatch Small Cap Growth Fund
1,211,109
1.19%
-195,813
1.07%
03/31/2018
iShares Nasdaq Biotechnology ETF
1,171,746
1.14%
-15,330
0.22%
09/06/2018
iShares Russell 2000 Growth ETF
975,051
0.96%
0
0.16%
09/06/2018
Vanguard Small Cap Growth Index Fund
729,574
0.72%
9,769
0.05%
07/31/2018
| Address |
Point Richmond Tech Center II
Richmond California 94804
United States
|
|
Employees
|
- |
| Website |
http://www.sangamo.com |
| Updated |
07/08/2019 |
| Sangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. |
